Mga Batayang Estadistika
| CIK | 930775 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Encision Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
Encision Completes $500,000 Private Placement Exhibit 99.1 August 21, 2025 Encision Completes $500,000 Private Placement Boulder, Colorado, August 21, 2025 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced that on August 19, 2025 it completed a $500,000 private placement of common stock wi |
|
| August 22, 2025 |
ENCISION INC. SECURITIES PURCHASE AGREEMENT Exhibit 10.1 ENCISION INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is entered into as of the 19th day of August, 2025 (the “Effective Date”) by and among ENCISION INC., a Colorado corporation (the “Company”), and the persons and entities named on the executed counterpart signature pages attached hereto (individually, a “Purchaser” and collectively, the “P |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-11789 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ¨ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exact |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 220549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitiv |
|
| July 10, 2025 |
Encision, Inc. Insider Trading Policy EXHIBIT 19.1 ENCISION INC. FINANCIAL POLICY & PROCEDURE MANUAL INSIDER TRADING POLICY POLICY NUMBER: 002 DATE: 2014 REVISION NUMBER: 5 PREPARED BY: Mala M Ray APPROVED BY: Greg Trudel Controller President I. PURPOSE: To specify standards of conduct applicable to employees, officers and directors and consultants and contractors of Encision Inc. (the “Company”) with respect to company securities tra |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-11789 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ¨ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10- |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Ex |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (E |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 15, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 15, 2024 |
Exhibit 99.1 August 15, 2024 Encision Reports First Quarter Fiscal Year 2025 Results Boulder, Colorado, August 15, 2024 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 first quarter that ended June 30, 20 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exact |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regist |
|
| July 15, 2024 |
Encision Reports Fourth Quarter Fiscal Year 2024 Results Exhibit 99.1 July 15, 2024 Encision Reports Fourth Quarter Fiscal Year 2024 Results Boulder, Colorado, July 15, 2024 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 fourth quarter that ended March 31, 202 |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-11789 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ¨ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10- |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 220549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitiv |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 (April 17, 2024) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Com |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Ex |
|
| February 14, 2024 |
Exhibit 99.1 February 14, 2024 Encision Reports Third Quarter Fiscal Year 2024 Results Boulder, Colorado, February 14, 2024 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 third quarter that ended Decembe |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-11789 NOTIFICATION OF LATE FILING (Check One) o Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form |
|
| February 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (E |
|
| November 14, 2023 |
Encision Reports Second Quarter Fiscal Year 2024 Results Exhibit 99.1 August 14, 2023 Encision Reports Second Quarter Fiscal Year 2024 Results Boulder, Colorado, August 14, 2023 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 second quarter that ended September |
|
| October 23, 2023 |
Exhibit 16.1 October 23, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Encision, Inc. Changes in Registrant’s Certifying Accountant We have read the statements made by Encision, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of the Current Report on Form 8-K of the Company dated October 23, 2023, a |
|
| October 23, 2023 |
Letter from GreenGrowth CPAs Inc. to the Securities and Exchange Commission, dated October 23, 2023. Exhibit 16.2 October 23, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Encision, Inc. Changes in Registrant’s Certifying Accountant We have read the statements made by Encision, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of the Current Report on Form 8-K of the Company dated October 23, 2023, a |
|
| October 23, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 (October 17, 2023) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 (August 30, 2023) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (C |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exact |
|
| August 9, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 3, 2023 |
Exhibit 99.1 August 3, 2023 Encision Reports First Quarter Fiscal Year 2024 Results Boulder, Colorado, August 3, 2023 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 first quarter that ended June 30, 2023 |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 220549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitiv |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-11789 ENCISION INC |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-11789 ENCISION INC. (Exact name of reg |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 22, 2023 |
Encision Reports Fourth Quarter Fiscal Year 2023 Results EXHIBIT 99.1 June 22, 2023 Encision Reports Fourth Quarter Fiscal Year 2023 Results Boulder, Colorado, June 22, 2023 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2023 fourth quarter that ended March 31, 202 |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Ex |
|
| February 7, 2023 |
Encision Reports Third Quarter Fiscal Year 2023 Results Exhibit 99.1 February 7, 2023 Encision Reports Third Quarter Fiscal Year 2023 Results Boulder, Colorado, February 7, 2023 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal year 2023 third quarter that ended Dece |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 (November 15, 2022) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation |
|
| November 17, 2022 |
New Line of Credit and Security Agreement with Pathward, N.A. dated November 15, 2022 Exhibit 10.1 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (E |
|
| November 14, 2022 |
Encision Reports Second Quarter Fiscal Year 2023 Results Exhibit 99.1 November 14, 2022 Encision Reports Second Quarter Fiscal Year 2023 Results Boulder, Colorado, November 10, 2022 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal year 2023 second quarter that ended |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 17, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exact |
|
| August 12, 2022 |
US Bank Note dated September 28, 2020 Exhibit 10.9 |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2022 |
Encision Reports First Quarter Fiscal Year 2023 Results Exhibit 99.1 August 9, 2022 Encision Reports First Quarter Fiscal Year 2023 Results Boulder, Colorado, August 9, 2022 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal year 2023 first quarter that ended June 30, |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| July 8, 2022 |
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 eciadef14a.htm DEFINITIVE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commis |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-11789 NOTIFICATION OF LATE FILING (Check One) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10- |
|
| June 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 16, 2022 |
Encision Reports Fourth Quarter Fiscal Year 2022 Results Exhibit 99.1 June 16, 2022 Encision Reports Fourth Quarter Fiscal Year 2022 Results Boulder, Colorado, June 16, 2022 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 fourth quarter that ended March 31, 202 |
|
| May 11, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 (May 5, 2022) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commissi |
|
| April 22, 2022 |
Encision Inc. 6797 Winchester Circle Boulder, CO 80301 Correspondence Encision Inc. 6797 Winchester Circle Boulder, CO 80301 April 22, 2022 Via EDGAR Correspondence Securities and Exchange Commission Washington, DC 20548 Attention: Lynn Dicker Office of Life Sciences Re: Encision Inc. Form 10-K for the Fiscal Year Ended March 31, 2021 Form 10-Q for the Quarter Ended December 31, 2021 File No. 001-11789 Dear Ms. Dicker: On April 22, 2022, Encision Inc. |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q/A (Amendment No. 2) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-117 |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-117 |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. |
|
| March 17, 2022 |
Encision Inc. 6797 Winchester Circle Boulder, CO 80301 Correspondence Encision Inc. 6797 Winchester Circle Boulder, CO 80301 March 17, 2022 Via EDGAR Correspondence Securities and Exchange Commission Washington, DC 20548 Attention: Lynn Dicker Office of Life Sciences Re: Encision Inc. Form 10-K for the Fiscal Year Ended March 31, 2021 Form 10-Q for the Quarter Ended December 31, 2021 File No. 001-11789 Dear Ms. Dicker: On March 17, 2022, Encision Inc. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Ex |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 10, 2022 |
Encision Reports Third Quarter Fiscal Year 2022 Results Exhibit 99.1 February 10, 2022 Encision Reports Third Quarter Fiscal Year 2022 Results Boulder, Colorado, February 10, 2022 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 third quarter that ended Decembe |
|
| December 10, 2021 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 (December 9, 2021) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) |
|
| December 10, 2021 |
Letter from Eide Bailly LLP to the Securities and Exchange Commission, dated December 9, 2021 Exhibit 16.1 December 9, 2021 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Commissioners: On December 9, 2021, we resigned as the independent registered public accounting firm for Encision, Inc. (the Company). We have read the Company?s disclosure set forth in Item 4.01, ?Change in Registrant?s Certifying Accountant? of the Company?s Current Report on Form 8-K, and are i |
|
| November 15, 2021 |
Supply Agreement dated August 23, 2021 between Auris Health, Inc. and Encision Inc. Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE SUPPLY AGREEMENT This SUPPLY AGREEMENT, effective as of the last date of signature below (the ?Effective Date?), is entered into between Auris Health, Inc |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (E |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 10, 2021 |
Encision Reports Second Quarter Fiscal Year 2022 Results Exhibit 99.1 November 10, 2021 Encision Reports Second Quarter Fiscal Year 2022 Results Boulder, Colorado, November 10, 2021 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 second quarter that ended Septe |
|
| August 25, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 (August 23, 2021) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (C |
|
| August 13, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exact |
|
| August 9, 2021 |
Encision Reports First Quarter Fiscal Year 2022 Results Exhibit 99.1 August 9, 2021 Encision Reports First Quarter Fiscal Year 2022 Results Boulder, Colorado, August 9, 2021 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2022 first quarter that ended June 3 |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021 S-8 1 ecias8-072221.htm FORM S-8 As filed with the Securities and Exchange Commission on July 26, 2021 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 84-1162056 (State or other jurisdiction of incorporation |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| June 23, 2021 |
Exhibit 4.3 |
|
| May 19, 2021 |
Exhibit 99.1 May 19, 2021 Encision Reports Fourth Quarter Fiscal Year 2021 Results Boulder, Colorado, May 19, 2021 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM?) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2021 fourth quarter that ended March 31 |
|
| May 19, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 12, 2021 |
PPP Promissory Note dated as of February 8, 2021 Exhibit 10.1 |
|
| February 12, 2021 |
10-Q 1 ecia10q-123120.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| February 4, 2021 |
Encision Reports Third Quarter Fiscal Year 2021 Results Exhibit 99.1 February 4, 2021 Encision Reports Third Quarter Fiscal Year 2021 Results Boulder, Colorado, February 4, 2021 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2021 third quarter that ended De |
|
| February 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 5, 2020 |
Encision Reports Second Quarter Fiscal Year 2021 Results Exhibit 99.1 November 5, 2020 Encision Reports Second Quarter Fiscal Year 2021 Results Boulder, Colorado, November 5, 2020 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2021 second quarter that ended |
|
| August 18, 2020 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 14, 2020 |
Exhibit 10.1 |
|
| August 14, 2020 |
10-Q 1 ecia10q-063020.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 21549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| August 6, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 6, 2020 |
Encision Reports First Quarter Fiscal Year 2021 Results Exhibit 99.1 August 6, 2020 Encision Reports First Quarter Fiscal Year 2021 Results Boulder, Colorado, August 6, 2020 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2021 first quarter that ended June 3 |
|
| June 30, 2020 |
DEF 14A 1 eciadef14a.htm DEFINITIVE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as per |
|
| June 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| May 14, 2020 |
Encision Reports Fourth Quarter Fiscal Year 2020 Results Exhibit 99.1 Encision Reports Fourth Quarter Fiscal Year 2020 Results BOULDER, Colo., May 14, 2020 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 fourth quarter that ended March 31, 2 |
|
| May 14, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 30, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 23, 2020 |
Encision Receives PPP Financing Exhibit 99.1 April 23, 2020 Encision Receives PPP Financing Boulder, Colorado, April 23, 2020 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced that it entered into an unsecured promissory note under the Paycheck Protection Program (the |
|
| April 23, 2020 |
PPP Promissory Note dated as of April 17, 2020 Exhibit 10.1 |
|
| February 13, 2020 |
ECIA / Encision, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| February 6, 2020 |
Encision Reports Third Quarter Fiscal Year 2020 Results Exhibit 99.1 Encision Reports Third Quarter Fiscal Year 2020 Results BOULDER, Colo., Feb. 6, 2020 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 third quarter that ended December 31, |
|
| February 6, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2020 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 13, 2019 |
ECIA / Encision, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 encision10q-093019.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| November 6, 2019 |
Financial Statements and Exhibits 8-K 1 tm192197518k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2019 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incor |
|
| November 6, 2019 |
Encision Reports Second Quarter Fiscal Year 2020 Results Exhibit 99.1 Encision Reports Second Quarter Fiscal Year 2020 Results BOULDER, Colo., Nov. 6, 2019 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 second quarter that ended September 3 |
|
| August 16, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2019 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 14, 2019 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 |
|
| August 14, 2019 |
ECIA / Encision, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 encision10q-063019.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| August 12, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2019 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 12, 2019 |
Encision Reports First Quarter Fiscal Year 2020 Results Encision Reports First Quarter Fiscal Year 2020 Results BOULDER, Colo., Aug. 12, 2019 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 first quarter that ended June 30, 2019. The Compan |
|
| June 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| June 14, 2019 |
ECIA / Encision, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| June 14, 2019 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary description of the securities is not complete and is qualified in its entirety by reference to our articles of incorporation, as amended, our bylaws and applicable provisions of Colorado corporation law. Our authorized capital stock consists of 110,000,000 shares of capital stock without par value, of which 100,000,000 shares are desig |
|
| February 14, 2019 |
ECIA / Encision, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| February 7, 2019 |
Encision Reports Third Quarter Fiscal Year 2019 Results Encision Reports Third Quarter Fiscal Year 2019 Results BOULDER, Colo., Feb. 7, 2019 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2019 third quarter that ended December 31, 2018. The Com |
|
| February 7, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2019 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 3, 2019 |
Securities Purchase Agreement dated December 19, 2018. EX-10.1 2 ex10x1.htm EXHIBIT 10.1 Exhibit 10.1 ENCISION INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into as of the 19th day of December, 2018 (the "Effective Date") by and among ENCISION INC., a Colorado corporation (the "Company"), and the persons and entities named on the executed counterpart signature pages attached hereto (individually, a |
|
| January 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2019 (December 19, 2018) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Co |
|
| January 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2019 (December 19, 2018) ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Co |
|
| January 3, 2019 |
Securities Purchase Agreement dated December 19, 2018. Exhibit 10.1 ENCISION INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into as of the 19th day of December, 2018 (the "Effective Date") by and among ENCISION INC., a Colorado corporation (the "Company"), and the persons and entities named on the executed counterpart signature pages attached hereto (individually, a "Purchaser" and collectively, the |
|
| January 2, 2019 |
Encision Completes Private Placement of Common Stock Exhibit 99.1 Encision Completes Private Placement of Common Stock Boulder, Colorado, December 20, 2018 - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced that it had completed a private placement of 875,000 shares of its common stock to C |
|
| January 2, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2019 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 21, 2018 |
ECIA / Encision, Inc. / KORNELSEN VERN D - SCHEDULE 13D/A Activist Investment SC 13D/A 1 encison13d.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Vern D. Kornelsen CMED Partners LLLP 4605 South Denice Drive Englewood, CO 80111 (303) 796-9192 (Name, Address a |
|
| November 13, 2018 |
ECIA / Encision, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| November 6, 2018 |
Encision Reports Second Quarter Fiscal Year 2019 Results EX-99.1 2 tv506175ex99-1.htm EXHIBIT 99.1 Encision Reports Second Quarter Fiscal Year 2019 Results BOULDER, Colo., Nov. 6, 2018 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2019 second q |
|
| November 6, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2018 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 13, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2018 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 13, 2018 |
ECIA / Encision, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exa |
|
| August 13, 2018 |
Exhibit 10.1 |
|
| August 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2018 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 2, 2018 |
Encision Reports First Quarter Fiscal Year 2019 Results Exhibit 99.1 Encision Reports First Quarter Fiscal Year 2019 Results BOULDER, Colo., Aug. 2, 2018 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2019 first quarter that ended June 30, 2018 |
|
| August 2, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2018 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 14, 2018 |
ECIA / Encision, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| June 11, 2018 |
ECIA / Encision, Inc. DEFINITIVE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive |
|
| May 7, 2018 |
Encision Reports Fourth Quarter Fiscal Year 2018 Results Encision Reports Fourth Quarter Fiscal Year 2018 Results BOULDER, Colo., May 7, 2018 /PRNewswire/ - Encision Inc. (OTC:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 fourth quarter that ended March 31, 2018. The Company posted quarterly net r |
|
| May 7, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2018 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 12, 2018 |
ECIA / Encision, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| February 12, 2018 |
Fifth Amendment to Office Building Lease dated November 9, 2017 Exhibit 10.1 FIFTH AMENDMENT TO LEASE This Fifth Amendment to Office Building Lease, effective 9 November, 2017, is entered into between 6797 Winchester, LLC, a Delaware limited liability company, successor in interest to Borealis Medical, LLC, ("Landlord"), and Encision, Inc., a Colorado Corporation ("Tenant"), and is made with reference to the following facts: A. Landlord's predecessor in intere |
|
| February 5, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2018 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 5, 2018 |
Encision Reports Third Quarter Fiscal Year 2018 Results Exhibit 99.1 Encision Reports Third Quarter Fiscal Year 2018 Results BOULDER, Colo., Feb. 5, 2018 /PRNewswire/ - Encision Inc. (OTC:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 third quarter that ended December 31, 2017. The Company posted |
|
| December 4, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 4, 2017 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 4, 2017 |
Encision Announces Death of VP-Product Development Officer Michael Biggs Encision Announces Death of VP-Product Development Officer Michael Biggs BOULDER, Colo. |
|
| November 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| November 2, 2017 |
Financial Statements and Exhibits 8-K 1 tv4781778k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2017 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorpo |
|
| November 2, 2017 |
Encision Reports Second Quarter Fiscal Year 2018 Results Encision Reports Second Quarter Fiscal Year 2018 Results BOULDER, Colo., Nov. 2, 2017 /PRNewswire/ - Encision Inc. (OTC: ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 second quarter that ended September 30, 2017. The Company posted quarterly |
|
| August 22, 2017 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Timothy J. |
|
| August 22, 2017 |
EX-99.2 Exhibit 99.2 TRADING DATA The following table sets forth all transactions in the Shares effected since the filing of Amendment No. 4. Except as noted below, all such transactions were effected in the open market through brokers and the price per share is net of commissions. Trade Date Buy/Sell Quantity of Shares Unit Cost Security 8/21/2017 Sell 40,000 $ 0.43 Common Stock 8/21/2017 Sell 24 |
|
| August 11, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 encision8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2017 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorpor |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. (Exa |
|
| July 27, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2017 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 27, 2017 |
Encision Reports First Quarter Fiscal Year 2018 Results Encision Reports First Quarter Fiscal Year 2018 Results BOULDER, Colo., July 27, 2017 /PRNewswire/ - Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 first quarter that ended June 30, 2017. The Company posted quarterly net revenu |
|
| July 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| June 15, 2017 |
EX-99.6 2 d412068dex996.htm EX-99.6 Exhibit 99.6 June 13, 2017 Encision, Inc. Board of Directors 6797 Winchester Circle Boulder, CO 80301 Dear Encision, Inc. Board of Directors, We are writing to express our disappointment with the board’s unilateral amendment to Encision’s bylaws on May 30, 2017. This amendment serves no purposes other than to increase the administrative burden on shareholders at |
|
| June 15, 2017 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Ti |
|
| June 14, 2017 |
Encision FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| May 31, 2017 |
First Amended and Restated Bylaws EX-3.1 2 ex3x1.htm EXHIBIT 3.1 Exhibit 3.1 FIRST AMENDED AND RESTATED BYLAWS OF ENCISION INC. EFFECTIVE AS OF MAY 30, 2017 ARTICLE I Shareholders Section 1. Annual Meeting. The annual meeting of the shareholders shall be held at such time of each year at a time and place to be set by the Board of Directors for the purpose of electing Directors and for the transaction of such other business as may |
|
| May 31, 2017 |
Exhibit 3.2 FIRST AMENDED AND RESTATED BYLAWS OF ENCISION INC. EFFECTIVE AS OF MAY , 2017 ARTICLE I Shareholders Section 1. Annual Meeting. The annual meeting of the shareholders shall be held at such time of each year at a time and place to be set by the Board of Directors for the purpose of electing Directors and for the transaction of such other business as may come before the meeting. Section |
|
| May 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2017 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 30, 2017 |
SD 1 encisionsd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Encision Inc. (Exact Name of Registrant as Specified in its Charter) Colorado 84-1162056 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6797 Winchester Circle Boulder, Colorado 80301 (Address of principal exec |
|
| May 10, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2017 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2017 |
Encision Reports Fourth Quarter Fiscal Year 2017 Results Encision Reports Fourth Quarter Fiscal Year 2017 Results BOULDER, Colo., May 10, 2017 /PRNewswire/ - Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2017 fourth quarter that ended March 31, 2017. The Company posted quarterly net reve |
|
| April 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2017 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2017 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 8, 2017 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Ti |
|
| March 8, 2017 |
EX-99.5 Exhibit 99.5 March 7, 2017 Gregory Trudel President & CEO Encision, Inc. 6797 Winchester Circle Boulder, CO 80301 Dear Greg, I appreciate the phone call this past Friday regarding our request to conduct necessary due diligence before making an offer for Encision. The board’s denial of our due diligence request was odd, especially when you agreed to it during my recent visit and in a subseq |
|
| February 14, 2017 |
Encision FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC. |
|
| February 14, 2017 |
Exhibit 31.1 CERTIFICATIONS I, Gregory Trudel, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Encision Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| February 14, 2017 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is made and effective 14 Nov 2016, BETWEEN: Gregory J. Trudel (the "Executive"), an individual with his main address at: 3327 Alexander Way, Broomfield, CO 80023. AND: Encision Inc. (the "Company"), an entity organized and existing under the laws of Colorado, with its head office located at: 6797 Winchester Circle, Bould |
|
| February 13, 2017 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Ti |
|
| February 13, 2017 |
EX-99.2 Exhibit 99.2 TRADING DATA Trade Date Buy/Sell Quantity of Shares Unit Cost Security 10/31/2016 Buy 900 $0.3283 Common Stock 11/2/2016 Buy 38,413 $0.2888 Common Stock 11/29/2016 Buy 40,000 $0.2153 Common Stock 11/30/2016 Buy 40,000 $0.1996 Common Stock 12/7/2016 Buy 500 $0.2860 Common Stock 12/7/2016 Buy 500 $0.3788 Common Stock 12/8/2016 Buy 40,000 $0.2635 Common Stock 12/14/2016 Buy 15,00 |
|
| February 13, 2017 |
ENCISION INC. CONFIDENTIAL NON-DISCLOSURE AGREEMENT EX-99.4 Exhibit 99.4 ENCISION INC. CONFIDENTIAL NON-DISCLOSURE AGREEMENT Encision Inc. (“Company”), a Colorado Corporation, having a principal place of business at 6797 Winchester Circle, Boulder, Colorado 80301 and The O.R. Company. (“Promisor”), having principal places of business at 1625 South Tacoma Way, Tacoma, WA 98409 USA and 122-124 Balmain Street Richmond, VIC 3121 Australia hereby agree |
|
| February 8, 2017 |
Exhibit 99.1 Encision Reports Third Quarter Fiscal Year 2017 Results; Sequential Quarterly Revenue Grows 4 Percent BOULDER, Colo., Feb. 8, 2017 /PRNewswire/ - Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2017 third quarter that en |
|
| February 8, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2017 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 19, 2017 |
EX-99.2 Exhibit 99.2 TRADING DATA Trade Date Buy/Sell Quantity of Shares Unit Cost Security 10/31/2016 Buy 900 $ 0.3283 Common Stock 11/2/2016 Buy 38,413 $ 0.2888 Common Stock 11/29/2016 Buy 40,000 $ 0.2153 Common Stock 11/30/2016 Buy 40,000 $ 0.1996 Common Stock 12/7/2016 Buy 500 $ 0.2860 Common Stock 12/7/2016 Buy 500 $ 0.3788 Common Stock 12/8/2016 Buy 40,000 $ 0.2635 Common Stock 12/14/2016 Bu |
|
| January 19, 2017 |
LETTER TO THE BOARD OF DIRECTORS OF THE COMPANY, DATED JANUARY 19, 2017 January 19, 2017 EX-99.3 Exhibit 99.3 LETTER TO THE BOARD OF DIRECTORS OF THE COMPANY, DATED JANUARY 19, 2017 January 19, 2017 Confidential Encision Inc. 6797 Winchester Circle Boulder, Colorado 80301 Re: Encision Inc. Acquisition Proposal Dear Encision Inc. Board of Directors: This law firm represents Timothy J. Wynne and Brett M. Telford who jointly own approximately 5.4% of the outstanding shares of common stoc |
|
| January 19, 2017 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D/A Activist Investment SC 13D/A 1 d329439dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securitie |
|
| December 27, 2016 |
ECIA / Encision, Inc. / WYNNE TIMOTHY J - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Encision Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29254Q104 (CUSIP Number) Timothy J. Wynne 1625 S |
|
| December 27, 2016 |
EX-99.2 Exhibit 99.2 TRADING DATA Trade Date Buy/Sell Quantity of Shares Unit Cost Security 10/31/2016 Buy 900 $ 0.3283 Common Stock 11/2/2016 Buy 38,413 $ 0.2888 Common Stock 11/29/2016 Buy 40,000 $ 0.2153 Common Stock 11/30/2016 Buy 40,000 $ 0.1996 Common Stock 12/7/2016 Buy 500 $ 0.2860 Common Stock 12/7/2016 Buy 500 $ 0.3788 Common Stock 12/8/2016 Buy 40,000 $ 0.2635 Common Stock 12/14/2016 Bu |
|
| December 27, 2016 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of |
|
| November 18, 2016 |
Employment Agreement, dated November 14, 2016, between Encision Inc. and Gregory J. Trudel Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is made and effective 14 Nov 2016, BETWEEN: Gregory J. Trudel (the "Executive"), an individual with his main address at: 3327 Alexander Way, Broomfield, CO 80023. AND: Encision Inc. (the "Company"), an entity organized and existing under the laws of Colorado, with its head office located at: 6797 Winchester Circle, Bould |
|
| November 18, 2016 |
8-K 1 encision8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2016 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incor |
|
| November 14, 2016 |
Encision FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENCISION INC |
|
| November 3, 2016 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2016 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 3, 2016 |
Encision Reports Second Quarter Fiscal Year 2017 Results EX-99.1 2 v452053ex99-1.htm EXHIBIT 99.1 Encision Reports Second Quarter Fiscal Year 2017 Results BOULDER, Colo., Nov. 3, 2016 /PRNewswire/ - Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2017 second quarter that ended September 30 |
|
| August 12, 2016 |
Encision FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2016 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2016 |
Encision FORM 10-Q FOR THE PERIOD ENDED 6/30/2016 (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 |
|
| August 2, 2016 |
Encision Reports First Quarter Fiscal Year 2017 Results Exhibit 99.1 Encision Reports First Quarter Fiscal Year 2017 Results BOULDER, Colo., Aug. 2, 2016 /PRNewswire/ - Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2017 first quarter that ended June 30, 2016. The Company posted quarterl |
|
| August 2, 2016 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2016 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| June 14, 2016 |
Encision FORM 10-K FOR THE FISCAL YEAR ENDED MARCH 31, 2016 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (Exact name of regis |
|
| June 14, 2016 |
Exhibit 10.11 LOAN AND SECURITY AGREEMENT ("Agreement") This Agreement dated 15 March, 2016, is an agreement between CRESTMARK BANK ("Crestmark"), and ENCISION INC, a Colorado corporation (''Borrower"). In this Agreement, Crestmark and Borrower are collectively the "Parties". Any person or entity who guarantees the obligations of Borrower (each a "Guarantor") is required to sign this Agreement. Th |
|
| May 17, 2016 |
SD 1 v440086sd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Encision Inc. (Exact Name of Registrant as Specified in its Charter) Colorado 84-1162056 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6797 Winchester Circle Boulder, Colorado 80301 (Address of principal execu |
|
| May 13, 2016 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2016 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 13, 2016 |
Encision Reports Fourth Quarter and Fiscal Year 2016 Results Exhibit 99.1 Encision Reports Fourth Quarter and Fiscal Year 2016 Results BOULDER, Colo., May 13, 2016 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 fourth quarter and year that ended March 31, 2016. The Comp |
|
| March 23, 2016 |
Encision FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2016 Encision Inc. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 8, 2016 |
ECIA / Encision, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 a16-3033110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| February 2, 2016 |
Encision Reports Third Quarter Fiscal Year 2016 Results Exhibit 99.1 Encision Reports Third Quarter Fiscal Year 2016 Results BOULDER, Colo., Feb. 2, 2016 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 third quarter that ended December 31, 2015. The Company posted q |
|
| February 2, 2016 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2016 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| October 28, 2015 |
Encision FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2015 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 28, 2015 |
Encision Reports Second Quarter Fiscal Year 2016 Results Exhibit 99.1 Encision Reports Second Quarter Fiscal Year 2016 Results BOULDER, Colo., Oct. 28, 2015 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 second quarter that ended September 30, 2015. The Company post |
|
| August 12, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2015 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENC |
|
| August 3, 2015 |
Encision Reports First Quarter Fiscal Year 2016 Results Encision Reports First Quarter Fiscal Year 2016 Results BOULDER, Colo., Aug. 3, 2015 /PRNewswire/ - Encision Inc. (PK:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 first quarter that ended June 30, 2015. The Company posted quarterly net reve |
|
| August 3, 2015 |
Financial Statements and Exhibits 8-K 1 v4167548k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2015 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporat |
|
| July 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| July 28, 2015 |
As filed with the Securities and Exchange Commission on July 28, 2015. Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 84-1162056 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe |
|
| June 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-11789 ENCISION INC. |
|
| June 3, 2015 |
SECOND AMENDMENT to AMENDED AND RESTATED Loan and security agreement EX-10.1 2 v412388ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECOND AMENDMENT to AMENDED AND RESTATED Loan and security agreement THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 31st day of May, 2015, by and between SILICON VALLEY BANK, a California corporation (“Bank”), and ENCISION INC., a Colorado corporation (“Borrower”). Recitals A. B |
|
| June 3, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2015 (May 31, 2015) ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission |
|
| May 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Encision Inc. (Exact Name of Registrant as Specified in its Charter) Colorado 84-1162056 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6797 Winchester Circle Boulder, Colorado 80301 (Address of principal executive offices) (Zip Code) Ma |
|
| May 27, 2015 |
Encision FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2015 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 27, 2015 |
Encision Reports Fourth Quarter And Fiscal Year 2015 Results EX-99.1 2 v411656ex99-1.htm EXHIBIT 99.1 Encision Reports Fourth Quarter And Fiscal Year 2015 Results BOULDER, Colo., May 27, 2015 /PRNewswire/ - Encision Inc. (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2015 fourth quarter and fiscal ye |
|
| April 3, 2015 |
ECIA / Encision, Inc. / KORNELSEN VERN D - SC 13D/A Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| February 6, 2015 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 |
|
| January 30, 2015 |
Financial Statements and Exhibits 8-K 1 v3998248k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2015 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorpor |
|
| January 30, 2015 |
Encision Reports Third Quarter Fiscal Year 2015 Results Encision Reports Third Quarter Fiscal Year 2015 Results BOULDER, Colo., Jan. 30, 2015 /PRNewswire/ - Encision Inc. (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2015 third quarter ended December 31, 2014. The Company posted quarterly net r |
|
| January 2, 2015 |
Encision SC 13D/A (Activist Acquisition of More Than 5% of Shares) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| January 2, 2015 |
ECIA / Encision, Inc. / Intertec Healthcare Management, L.L.C. - SC 13D/A Activist Investment SC 13D/A 1 a15-10591sc13da.htm SC 13D/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden SCHEDULE 13D hours per response. . . . . . . .14.5 Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENCISION INC. (Name of Issuer) COMMON STOCK, NO PAR VALUE (Title of Class of Securities) |
|
| November 13, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-1178 |
|
| October 31, 2014 |
Encision Reports Second Quarter Fiscal Year 2015 Results Encision Reports Second Quarter Fiscal Year 2015 Results BOULDER, Colo., Oct. 31, 2014 /PRNewswire/ - Encision Inc. (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2015 second quarter ended September 30, 2014. The Company posted quarterly ne |
|
| October 31, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2014 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 3, 2014 |
ECIA / Encision, Inc. / SHEEDY CHARLES E - FORM SC 13G/A Passive Investment Form SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENCISION INC. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 29254Q104 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| August 14, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2014 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 ENC |
|
| July 29, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2014 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 29, 2014 |
Encision Reports First Quarter Fiscal Year 2015 Results Encision Reports First Quarter Fiscal Year 2015 Results BOULDER, Colo., July 29, 2014 /PRNewswire/ - Encision Inc. (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2015 first quarter ended June 30, 2014. The Company posted quarterly net reven |
|
| July 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 0-28604 ENCISION INC. (E |
|
| May 23, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2014 ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 23, 2014 |
FIRST AMENDMENT to AMENDED AND RESTATED Loan and security agreement FIRST AMENDMENT to AMENDED AND RESTATED Loan and security agreement THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 19th day of May, 2014, but effective as of May 10, 2014, by and between SILICON VALLEY BANK, a California corporation (“Bank”), and ENCISION INC. |
|
| February 14, 2014 |
Table of Contents As filed with the Securities and Exchange Commission on February 14, 2014 No. |
|
| February 11, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-11789 |
|
| January 31, 2014 |
Encision Reports Third Quarter Fiscal Year 2014 Results Encision Reports Third Quarter Fiscal Year 2014 Results BOULDER, Colo., Jan. 30, 2014 /PRNewswire/ - Encision Inc. (OTC PINK: ECIA), a medical device company owning patented surgical technology that prevents stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2014 third quarter ended December 31, 2013. The Company posted quarterly revenue of |
|
| January 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2014 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 23, 2014 |
ECIA / Encision, Inc. / KORNELSEN VERN D - SC 13D/A Activist Investment SC 13D/A 1 a14-41781sc13da.htm SC 13D/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden SCHEDULE 13D hours per response. . . . . . . .14.5 Under the Securities Exchange Act of 1934 (Amendment No. 4)* ENCISION INC. (Name of Issuer) COMMON STOCK, NO PAR VALUE (Title of Class of Securities) |
|
| January 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2014 ENCISION, INC. (Exact name of registrant as specified in its charter) Colorado 0-28604 84-1162056 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 8, 2014 |
Encision Files 510(k) with FDA for AEM® Simplification Product Encision Files 510(k) with FDA for AEM® Simplification Product BOULDER, Colo., Jan. 8, 2014 /PRNewswire/ - Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that prevents stray electrosurgical burns in minimally invasive surgery, announced today that it has filed a premarket notification under Section 510(k) with the FDA of its intent to market what has previous |
|
| December 23, 2013 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and effective December 17, 2013. BETWEEN: Gregory J. Trudel (the “Executive”), an individual with his main address at: 3327 Alexander Way, Broomfield, CO 80023. AND: Encision Inc. (the “Company”), an entity organized and existing under the laws of Colorado, with its head office located at: 6797 Winchester Circle, |
|
| December 23, 2013 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 17, 2013 , between Encision Inc., a Colorado corporation (the “Company”), and the persons and entities named on the executed counterpart signature pages attached hereto (individually, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursu |
|
| December 23, 2013 |
ENCISION INC. SECURITIES PURCHASE AGREEMENT EX-10.1 2 a13-269541ex10d1.htm EX-10.1 Exhibit 10.1 ENCISION INC. SECURITIES PURCHASE AGREEMENT ENCISION INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is entered into as of the 17th day of December, 2013 (the “Effective Date”) by and among ENCISION INC., a Colorado corporation (the “Company”), and the persons and entities named on the executed counterpart |
|
| December 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2013 (December 17, 2013) ENCISION INC. (Exact name of registrant as specified in its charter) Colorado 001-11789 84-1162056 (State or other jurisdiction of incorporation) |
|
| December 18, 2013 |
Encision Announces New President and CEO Encision Announces New President and CEO BOULDER, Colo., Dec. 18, 2013 /PRNewswire/ - Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that prevents stray electrosurgical burns in minimally invasive surgery, today announced the appointment of Greg Trudel as its new President and CEO. A proven manager with over 25 years of experience in the surgical devices mark |
